European Commission homes in on dual pricing by pharma companies
This article was originally published in SRA
Executive Summary
In a move aimed at establishing how pharmaceutical companies are dealing with the question of parallel trade, the European Commission has asked a number of firms in Spain for information on how they price their products for sale to wholesalers1.